Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Gross Profit: 2023-2025

Historic Gross Profit for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $348,000.

  • NewAmsterdam Pharma Co N.V's Gross Profit fell 98.80% to $348,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year increase of 4.91%. This contributed to the annual value of $45.6 million for FY2024, which is 223.37% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Gross Profit stood at $348,000 for Q3 2025, which was down 98.18% from $19.1 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Gross Profit ranged from a high of $29.1 million in Q3 2024 and a low of $348,000 during Q3 2025.
  • Its 3-year average for Gross Profit is $7.6 million, with a median of $2.9 million in 2023.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Gross Profit surged by 1,490.54% in 2024 and then tumbled by 98.80% in 2025.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Gross Profit stood at $803,000 in 2023, then surged by 1,490.54% to $12.8 million in 2024, then slumped by 98.80% to $348,000 in 2025.
  • Its Gross Profit stands at $348,000 for Q3 2025, versus $19.1 million for Q2 2025 and $3.0 million for Q1 2025.